So-Ra Park

Title: So-Ra Park: Innovator in Cancer Treatment

Introduction

So-Ra Park is a prominent inventor based in Yongin, South Korea. She has made significant contributions to the field of biotechnology, particularly in the development of antibody variants for cancer treatment. Her innovative work focuses on enhancing the efficacy of therapeutic agents against cancer.

Latest Patents

So-Ra Park holds a patent for "Anti-ErbB2 antibody variants." This invention relates to antibody variants or antigen-binding fragments that are capable of binding to ErbB2 with high affinity. The antibody variants are designed to effectively prevent or treat various cancers with a low dosage, showcasing their potential in clinical applications.

Career Highlights

So-Ra Park is affiliated with Chong Kun Dang Pharmaceutical Corporation, where she continues to advance her research and development efforts. Her work is pivotal in the ongoing fight against cancer, and her innovative approaches are recognized within the pharmaceutical industry.

Collaborations

So-Ra Park collaborates with esteemed colleagues, including Seung-Kee Moon and Ki-Young An. These partnerships enhance the research environment and contribute to the successful development of new therapeutic solutions.

Conclusion

So-Ra Park's contributions to cancer treatment through her innovative antibody variants exemplify the impact of dedicated research in biotechnology. Her work not only advances scientific knowledge but also holds promise for improving patient outcomes in cancer therapy.